Vestronidase alfa clinical trials
Also written UX003, Mepsevii ™ and recombinant human beta-glucuronidase.
How each study uses vestronidase alfa is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 15 Nov 2017 · MEPSEVII · BLA 761047 (FDA, Drugs@FDA)
- European Union
- 23 Aug 2018 · Mepsevii · EMEA/H/C/004438 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
4 studies that test it; most in 2015 (2)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Studies
Open first, then newest update. How each study uses vestronidase alfa is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- A Study of UX003 Recombinant Human Beta-Glucuronidase (rhGUS) Enzyme Replacement Therapy in Subjects With Mucopolysaccharidosis Type 7, Sly Syndrome (MPS 7)CompletedPhase 3Ultragenyx Pharmaceutical IncNCT02432144Written as UX003How we know
- A Phase 3 Study of UX003 Recombinant Human Betaglucuronidase (rhGUS) Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis Type 7 (MPS 7)CompletedPhase 3Ultragenyx Pharmaceutical IncNCT02230566Written as UX003How we know
- Study of UX003 Recombinant Human Beta-Glucuronidase (rhGUS) Enzyme Replacement Treatment in Mucopolysaccharidosis Type 7, Sly Syndrome (MPS 7) Patients Less Than 5 Years of AgeCompletedPhase 2Ultragenyx Pharmaceutical IncNCT02418455Written as UX003How we know
- An Open-Label Phase 1/2 Study to Assess the Safety, Efficacy and Dose of Study Drug UX003 Recombinant Human Beta-glucuronidase (rhGUS) Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis Type 7 (MPS 7)CompletedPhase 1/2Ultragenyx Pharmaceutical IncNCT01856218Written as UX003How we know
Codes
What other systems call vestronidase alfa · ClinicalTrials.gg INT001183
- MeSH (NLM) C000654126vestronidase alfaConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 7XZ4062R17VESTRONIDASE ALFAConfirmed FDA, NLM
- RxNorm 1989819One source FDA
- NCI Thesaurus C152871Vestronidase AlfaOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000654126 | vestronidase alfa | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 7XZ4062R17 | VESTRONIDASE ALFA | Confirmed FDA, NLM |
| RxNorm | 1989819 | — | One source FDA |
| NCI Thesaurus | C152871 | Vestronidase Alfa | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.